ENDRA Life Sciences, Inc. NDRAU 深 滬
已收盤 10-08 16:00:00 美东时间
4.50
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 4.50
- 總市值 1490.87万
- 52周最高 5.59
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 4.01
- 委 比 0.00%
- 總股本 331.30万
- 歷史最高 5.59
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.01
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
Robinhood Weighs Prediction-Market Acquisitions: Report
Robinhood Markets, Inc. (NASDAQ:HOOD) shares traded lower in the premarket sess...
10-14 21:43
Why Ericsson Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Shares of Telefonaktiebolaget LM Ericsson – ADR (NASDAQ:ERIC) rose sharply in p...
10-14 17:45
ENDRA Life Sciences Gains Momentum With Crypto-Focused Treasury Plan
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced $4.9M in funding to launch a digital asset treasury strategy.
10-14 00:24
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38
Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $46 to $38.
09-22 17:54
ENDRA Life Sciences Q2 EPS $(1.71) Beats $(2.27) Estimate
ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(1.71) per share which beat the analyst consensus estimate of $(2.27) by 24.67 percent. This is a 2037.5 percent decrease over losses of $(0.08) per share
08-15 04:17
快讯 | ENDRA生命科学公司第二季度运营支出为120万美元
ENDRA Life Sciences Q2 Operating Expenses USD 1.2 Million
08-15 04:05
ENDRA Life Sciences Launches Bitcoin Treasury Strategy, Forms Advisory Board With James Altucher, James Manning, And Rayne Steinberg
The Board of Directors (the "Board") of ENDRA Life Sciences Inc. (the "Company") has authorized the Company to develop and pursue a cryptocurrency treasury strategy. Following this authorization, the Company has:
07-23 21:08
ENDRA Life Sciences Expects Q2 2025 Loss Of ~$1.3M, No Revenue, And ~$2.6M In Total Assets
Recent Financial ResultsBelow is a summary of certain preliminary estimates regarding our financial results for the quarter ended June 30, 2025. This preliminary financial information is based upon our estimates and is
07-10 04:55
快讯 | ENDRA Life Sciences Inc - 预计2025年第二季度没有营业收入 - SEC文件
ENDRA Life Sciences Inc - Expects No Revenue for Q2 2025 - SEC Filing
07-10 04:52
